Preeclampsia (toxemia in pregnancy) is a disorder of pregnancy that is characterized by hypertension (high blood pressure) and proteinuria (excessive protein in the urine), often including edema (swelling) and occasionally involving thrombocytopenia (low platelets) or liver function abnormalities.
Preeclampsia complicates 5-7% of pregnancies in otherwise healthy patients.
The risk of preeclampsia is highest in primagravidas (women in their first pregnancy) and in women who have had minimal exposure to sperm (having used barrier methods of contraception, e.g. condoms).
A person with mild preeclampsia may feel perfectly well. Therefore, it is important to attend all prenatal checkups to spot this condition early. The symptoms of severe preeclampsia, which can develop during the last weeks of pregnancy are headaches, blurred vision, intolerance for bright light, nausea and vomiting, and salt and water retention. It may progress to eclampsia, the symptoms of which are convulsions (seizures) and sometimes unconsciousness.
The diagnosis of preeclampsia is primarily, but not exclusively, made on the basis of proteinuria and edema in a hypertensive pregnant woman. Other factors helpful in making the diagnosis are hemoconcentration, hyperreflexia, hypoalbuminemia, liver function abnormalities, thrombocytopenia, and hyperuricemia. Abnormal prostaglandin synthesis may be the pivotal defect causing increased peripheral vascular resistance, severe vasoconstriction, endothelial injury and secondary hypertension.
Management of preeclampsia has centered on aggressive maternal/fetal assessment and earliest safe delivery. Frequent monitoring of maternal blood pressure, urinary protein excretion, weight change, and symptoms is mandatory. Regular biophysiologic assessment of the fetus is also essential.
Most patients with preeclampsia are treated on an inpatient basis. If the preeclampsia is mild and blood pressure is adequately controlled with no signs of impending seizure, patients may be managed at home with bed rest. In this case, blood pressure should be monitored twice daily and fetal status should be assessed at least twice weekly with a non-stress test and a biophysiologic profile. Delivery at maturity is still mandatory in this group of patients, unless induction has been unsuccessful. In the latter case, cesarean section or a second trial of induction must be considered.
If the condition is not properly treated, the patient may develop eclampsia, a potentially fatal condition involving coma and convulsions.
The backbone of management continues to be parenteral (intravenous) administration of magnesium sulfate and delivery as soon as the fetus is mature or when maternal risks outweigh any risks to the fetus. The main purpose of this therapy is to inhibit progression to eclampsia. Magnesium may be given intramuscularly or intravenously.
Several studies imply that harmful free radicals called lipid peroxides contribute to preeclampsia [Khan KS, Chien Pl. Brit J of Obst & Gyn 1997;104(10): pp.1173-9], and that women with this condition are low in the antioxidants that combat them. [Ziari SA, et al. Am Jl of Perinat 1996;13(5): pp.287-91]
The U.S. RDA is 70mg. NOTE: Be very careful to avoid high doses.
Your body is a highly complex, interconnected system. Instead of guessing at what might be wrong, let us help you discover what is really going on inside your body based on the many clues it is giving.
Our multiple symptom checker provides in-depth health analysis by The Analyst™ with full explanations, recommendations and (optionally) doctors available for case review and answering your specific questions.